- Home
- ATYR vs TCRX Comparison
ATYR vs TCRX Comparison
Compare ATYR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- TCRX
- Stock Information
- Founded
- ATYR 2005
- TCRX 2018
- Country
- ATYR United States
- TCRX United States
- Employees
- ATYR N/A
- TCRX N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- TCRX Health Care
- Exchange
- ATYR Nasdaq
- TCRX Nasdaq
- Market Cap
- ATYR 228.1M
- TCRX 257.5M
- IPO Year
- ATYR 2015
- TCRX 2021
- Fundamental
- Price
- ATYR $3.03
- TCRX $4.26
- Analyst Decision
- ATYR Strong Buy
- TCRX Strong Buy
- Analyst Count
- ATYR 4
- TCRX 5
- Target Price
- ATYR $19.25
- TCRX $11.40
- AVG Volume (30 Days)
- ATYR 927.6K
- TCRX 271.8K
- Earning Date
- ATYR 11-07-2024
- TCRX 11-12-2024
- Dividend Yield
- ATYR N/A
- TCRX N/A
- EPS Growth
- ATYR N/A
- TCRX N/A
- EPS
- ATYR N/A
- TCRX N/A
- Revenue
- ATYR $235,000.00
- TCRX $9,362,000.00
- Revenue This Year
- ATYR N/A
- TCRX N/A
- Revenue Next Year
- ATYR $2,057.69
- TCRX $3.10
- P/E Ratio
- ATYR N/A
- TCRX N/A
- Revenue Growth
- ATYR N/A
- TCRX N/A
- 52 Week Low
- ATYR $1.14
- TCRX $3.92
- 52 Week High
- ATYR $3.80
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- ATYR 51.78
- TCRX 37.28
- Support Level
- ATYR $2.88
- TCRX $3.92
- Resistance Level
- ATYR $3.80
- TCRX $6.23
- Average True Range (ATR)
- ATYR 0.24
- TCRX 0.42
- MACD
- ATYR -0.07
- TCRX -0.12
- Stochastic Oscillator
- ATYR 22.22
- TCRX 14.75
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.